32
Dr. Joaquim Bellmunt is the Director of the Bladder Cancer Center at the Dana-Farber Cancer Institute (DFCI) and the Dana-Farber/Brigham and Women’s Cancer Center, Harvard University, United States. He combines this work with the management of the Dr. Bellmunt Cancer Institute based at the University Hospital Quirón Dexeus in Barcelona. He is also the Associate Professor of Medicine at Harvard Medical School and Attending Physician of Solid Tumor Oncology at DFCI.
Dr. Bellmunt graduated in Medicine and Surgery in 1982 and received his PhD in 1989, both from the Autonomous University of Barcelona, Spain. He completed his Medical Oncology Residency at the University Hospital Vall d’Hebron, in Barcelona, Spain. He gained his European Certificate of Medical Oncology in London and New York. He has worked as Chief of the Solid Tumor Oncology Service of the Hospital del Mar, Spain
In 2008 Dr. Bellmunt was appointed as a Visiting Associate Professor at Harvard University. He has also worked as the Associate Professor of Medicine at Pompeu Fabra University, Spain, and has managed the Dr. Bellmunt Cancer Institute.
His research interests lie in clinical genitourinary oncology, and translational and early clinical research in the area of growth factor receptors and downstream molecules as targets for cancer therapy.
Dr. Bellmunt is a member of the American Association for Cancer Research, American Society of Clinical Oncology, the European Society for Medical Oncology, and the Spanish Society of Medical Oncology. He has also been part of the American Congress Scientific Committee of the American Society of Clinical Oncology - Genitourinary. He is Past-President and Co-founder of the Spanish Oncology Genitourinary Group (SOGUG), a Consultant for the EORTC - GU Group, and Chairman of the group’s Advanced Bladder Committee. Dr. Bellmunt reviews publications for the Journal of Clinical Oncology, Annals of Oncology, European Urology, European Journal of Cancer, the British Journal of Urology International, and the Journal of Urology, among others.
Recent publications include:• Sonpavde, G., Pond, G.R., Fougeray, R., et al. (2013) Time from
prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. European Urology. 4: 717–23.
• Sonpavde, G., Galsky, M.D., and Bellmunt, J. (2013) A new approach to second-line therapy for uroethlial cancer? The Lancet Oncology. 14: 682–4.
• Meeks, J.J., Bellmunt, J., Bochner, B.H., et al. (2012) A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. European Urology. 62: 523–33.
Dr. Joaquim Bellmunt has reported consultancy and/or honoraria fees from Pierre Fabre and Pfizer.
Doctor
JOAQUIM BELLMUNTMD, PhD
Director of the Bladder Cancer Centre
Harvard Medical School
Boston, USA
Dr. Filippo de Braud, MD, is currently Director of the Medical Oncology Department and Division of the National Cancer Institute in Milan, Italy, where his principal area of expertise is clinical research in oncology. In 1984, Dr de Braud received his medical degree in medicine from the University of Milan. He continued his training in oncology at various institutions, including the Royal Free Hospital School of Medicine, London, UK, Wayne State University, Detroit, MI, USA, and the Institute Gustave Roussy in Paris, France. He has held clinical posts at the European Institute of Oncology, where he was appointed Deputy Director of the Medical Oncology Division in 1994, later becoming Director of Division of Clinical Pharmacology and New Drugs Development since August 2011 when he was appointed as Chief of Division of Medical Oncology at National Cancer Institute, Milan.
He is leading teams of researchers focusing on the development of new drugs (Phase I and early Phase II studies) and teaches at universities in Milan, Rome and Ferrara. Since 2000, he has been appointed Scientific Advisor and Member of Committee at the Italian Medicine Agency AIFA, the Ministry of Health, and several pharmaceutical companies.
Dr de Braud is the author or co-author of over 200 publications in medical oncology. Recent publications include:• Grassi P, Verzoni E, Mariani L, et al. Prognostic Role of Pancreatic
Metastases From Renal Cell Carcinoma: Results From an Italian Center. Clin Genitourin Cancer. 2013 Jun 19. pii: S1558–7673(13)00083–9. doi: 10.1016/j.clgc.2013.04.022. [Epub ahead of print]
• Pietrantonio F, De Braud F, Da Prat V, et al. A review on biomarkers for prediction of treatment outcome in gastric cancer. Anticancer Res. 2013 Apr;33(4):1257–66
Dr. De Braud has declared no potential conflicts of interest.
Doctor
FILIPPO DE BRAUDMD
Director, Medical Oncology Division
National Cancer Institute
Milan, Italy
Dr. Raffaele Califano works as a Consultant Medical Oncologist at The Christie cancer hospital and the University Hospital of South Manchester, both located in Manchester, United Kingdom.
Dr. Califano graduated in Medicine and Surgery in 2003, and completed Specialist Training in Medical Oncology in 2007 at the University of Perugia, Italy. From 2008 to 2012, Dr. Califano worked as Clinical Research Fellow with the Lung and Melanoma Team at The Christie. He has been involved in several clinical trials in Lung Cancer and Melanoma. He has developed a particular interest for molecularly-driven clinical trials in advanced lung cancer, and also has interest in thoracic malignancies.
Dr. Califano is a member of the Manchester Lung Cancer Group, the British Thoracic Oncology Group (BTOG), and the International Association of Study of Lung Cancer (IASLC). He serves as Chairman of the Young Oncologists Committee of the European Society for Medical Oncology (ESMO). Dr Califano is the author of several papers in peer-reviewed international journals; he has been an invited speaker to national and international oncology meetings.
Recent publications include:• Califano R, Landi L, Cappuzzo F. Prognostic and predictive
value of K-RAS mutations in non-small cell lung cancer. Drugs 2012;71(Suppl 1):28–36.
• Califano R, Abidin AZ, Peck R, et al. Management of small cell lung cancer: recent developments for optimal care. Drugs 2012;72(4):471–90.
Dr. Raffaele Califano has reported consultancy and/or honoraria fees from Roche, Lilly, Boehringer Ingelheim and Pfizer.
Doctor
RAFFAELE CALIFANOMD
Consultant in Medical Oncology
The Christie NHS Foundation Trust and University
of South Manchester
Manchester, United Kingdom
Dr. Fatima Cardoso is Director of the Breast Cancer Unit at the Champalimaud Cancer Center in Lisbon, Portugal.
Dr. Cardoso earned her medical degree at the University of Porto, Portugal, and then worked for ten years as an Assistant Professor at the Medical Oncology Clinic of the Jules Bordet Institute, Belgium. She is board-certified in Medical Oncology and Internal Medicine. Dr. Cardoso is interested in the biology of breast cancer, prognostic and predictive markers of responses to systemic therapy, and new anticancer agents. She is actively involved in a number of phase I, II, and III breast cancer clinical trials.
Dr. Cardoso is involved in numerous professional organizations such as the European Society for Medical Oncology, the European Cancer Organization, the European Organization for the Research and Treatment of Cancer, the American Society of Clinical Oncology, and the American Association for Cancer Research. She serves on several committees including the ECCO Board of Directors and serves as EORTC Secretary General. She is the Breast Cancer Program Coordinator of the European School of Oncology, Co-chair of the Advanced Breast Cancer International Consensus Guidelines Conference (ABC), Vice-chair of the EORTC-Breast Cancer Group, Editor-in-Chief of The Breast Journal, Associate Editor of the European Journal of Cancer and an Editorial Board Member for several other journals. She has authored over 200 publications and has presented her work nationally and internationally.
Recent publications include:• Senkus, E., Kyriakides, S., Penault-Llorca, F., et al. (2013) Primary
breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. [Epub ahead of print]
• Cardoso, F., Harbeck, N., Fallowfield, L., et al. (2012) Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 23: vii11–9.
• Goldhirsch A, Winer EP, Coates AS, et al. (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 24(9):2206–23.
Dr. Fatima Cardoso has reported consultancy and/or honoraria fees from Eisai, Roche, Glaxo SK, Celgene, Astra-Zeneca, Novartis, Pfizer, Astellas, GE Oncology, Merck-Sharp, Merus, BV, and Genetech.
Doctor
FATIMA CARDOSOMD
Director Breast Cancer Unit
Champalimaud Cancer Center
Lisbon, Portugal
Dr. Paolo G. Casali is Head of the Adult Sarcoma Medical Oncology Unit at the Istituto Nazionale Tumori in Milan, Italy, and serves as Secretary of the Ethics Committee at this institution.
Dr. Casali received his medical degree in 1984 and he was certified in Hematology in 1987 at the University of Milan, Italy. He is also certified in Clinical Oncology from the University of Parma, Italy. He holds the ESMO Certificate in Medical Oncology.
Dr. Casali’s clinical and research activities focus on rare tumors, especially adult sarcomas, including gastrointestinal stromal tumors and uncommon histotypes.
An active member of ESMO, Dr. Casali serves on the executive board and chairs the Public Policy Committee. He is a member of the Guidelines Working Group. He is also a member of the Policy Committee of the European Cancer Organisation (ECCO), and the European Organisation for Research and Treatment of Cancer (EORTC) – Soft Tissue & Bone Sarcoma Group. Dr. Casali chairs the Italian Network on Rare Tumors and is Secretary of the Italian Sarcoma Group, a national cooperative group for clinical and translational research on soft tissue and bone sarcomas. He is an editor of START (State-of-the-Art Oncology in Europe), an Italian-based, European state-of-the-art instrument on cancer treatment. Dr. Casali serves on the editorial board for Cancer Treatment Reviews, and is Editor-in-Chief of Clinical Sarcoma Research.
Recent publications include:• Stacchiotti, S., Tortoreto, M., Bozzi, F., et al. (2013) Dacarbazine
in solitary fibrous tumor: a case series analysis and preclinical evidence vis-à-vis temozolomide and antiangiogenics. Clinical Cancer Research. [Epub ahead of print]
• Gronchi, A. and Casali, P.G. (2013) Adjuvant Therapy for High-Risk Soft Tissue Sarcoma in the Adult. Current Treatment Options in Oncology. [Epub ahead of print]
• Casali, P.G., Fumagali, E. and Gronchi, A. (2012) Adjuvant therapy of gastrointestinal stromal tumors (GIST). Current Treatment Options in Oncology. 13: 277–84.
Dr. Casali has reported honoraria for consultancy/advisory role and/or for lectures, and/or had travel coverage for medical meetings from: Amgen Domplé, ARIAD, Bayer, Glaxo SK, Infinity, Janssen Cilag, Merck SD, Novartis, Pfizer, PharmaMar, Sanofi-Aventis. His Unit carried out research sponsored or supported by: Amgen Dompé, Bayer, Merck SD, Glaxo SK, ImClone, Infinity, Janssen Cilag, Lilly, Molmed, Novartis, Pfizer, PharmaMar, Roche, Sanofi, Schering Plough.
Doctor
PAOLO G. CASALIMD
Head of Adult Mesenchymal Tumor Medical
Oncology Unit
Istituto Nazionale dei Tumori
Milan, Italy
Dr. Vittoria Colia is a Medical Oncology Fellow working in the Adult Mesenchymal Tumor Medical Oncology Unit at the Istituto Nazionale Tumori in Milan, Italy.
Dr. Colia received her medical degree in 2009, and then trained at Sacco Hospital and Igea Clinic, Milan. Before completing her studies, she worked as a Medical Student Volunteer at the Institute for Indian Mother and Child ONLUS, in Kolkata, India. Her clinical and research activities focus on adult sarcomas.
Dr Colia is a member of the European Society for Medical Oncology (ESMO).
Dr. Colia has declared no potential conflicts of interest.
Doctor
VITTORIA COLIAMD
Adult Mesenchymal Tumor Medical Oncology Unit
Fondaz IRCCS Istituto Nazionale Tumori
Milan, Italy
Professor Carlo Aschele is Head of the Medical Oncology and Haematology Unit at the Ospedale del Felettino, Italy. He also has a post as Professor of Medical Oncology in the School of Specialization in Medical Oncology at the University of Genoa, Italy.
Prof. Aschele received his medical degree from the University of Genoa, Italy. He then specialized in Medical Oncology and served as Research Fellow at the Memorial Sloan-Kettering Cancer Center, USA. Receiving a PhD in Oncology from the University of Bologna, Italy, Prof. Aschele worked as a Consultant Medical Oncologist and as Assistant Medical Director at the National Institute for Cancer Research in Genoa, Italy. His research has focused on the treatment of gastrointestinal cancer, including the development and clinical assessment of new drugs and regimens.
Prof. Aschele is a member of the American Society of Clinical Oncology, the American Association for Cancer Research, and the Italian Association of Medical Oncology. He helped to set up and still chairs the STAR-Network, an Italian network of hospital and university centers conducting multidisciplinary clinical trials in gastrointestinal cancer.
Prof. Aschele has authored over 50 peer-reviewed scientific publications in indexed medical journals. He has served on the editorial board of Oncology Reports and serves as a reviewer for the British Journal of Cancer, Critical Reviews in Oncology/Hematology, Annals of Oncology, and the Journal of Clinical Oncology.
Recent publications include:• Aschele, C., Coinini, L., Lonardi. S., et al. (2011) Primary tumor
response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. Journal of Clinical Oncology. 29: 2773-80.
• Aschele, C. and Lonardi, S. (2007) Addition of weekly oxalipatin to standard preoperative chemoradiation for locally advanced rectal cancer. Jounral of Clinical Oncology. 25: 602–3.
• Aschele, C., Friso, M.L., Pucciarelli, S., et al. (2005) A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. Annals of Oncology. 16: 1140–6.
Professor Carlo Aschele has reported no conflict of interest.
Professor CARLO ASCHELE MD, PhD
Head of Medical Oncology and Hematology
Felettino Hospital
La Spezia, Italy
Dr. Katrin Lisa Conen is Medical Oncologist at the Department of Medical Oncology of the University Hospital in Basel, Switzerland.
Dr. Conen graduated in Medicine in 2003 from the University of Würzburg, Germany and was awarded her PhD in 2005. She then completed a fellowship in Internal Medicine in Basel, Switzerland. From 2006 to 2008, she undertook a research fellowship focusing on bone biology in Massachusetts General Hospital, USA. She was registered as an Internist in 2010 and as a Medical Oncologist in 2013.
She has specialist interests in brain tumour treatment and in supportive and palliative medicine. Dr. Conen has co-authored eight peer-reviewed articles and one book chapter.
Recent publications include:• Conen, K.L., Jeanneret, C., Hecker, B., Cathomas, G., and
Biedermann, B.C. (2006) Acute occlusive large vessel disease leading to fatal stroke in a patient with systemic lupus erythematosus: arteritis or atherosclerosis? Arthritis and Rheumatism. 54: 908–913.
• Conen, K.L., Nishimori, S., Provot, S., et al. (2009) The transcriptional cofactor Lbh regulates angiogenesis and endochondral bone formation during fetal bone development. Developmental Biology. 333: 348–358.
Dr. Katrin Lisa Conen has reported no consultancy or honoraria fees.
Doctor
KATRIN LISA CONENMD
Medical Oncologist
Department of Medical Oncology
University Hospital in Basel, Switzerland
Professor Andreas Dietz is the Director of the ENT Department at the University Hospital of Leipzig, Germany.
Prof. Dietz undertook his early medical education in Budapest, Hungary, and in Giessen and Heidelberg, Germany, receiving his medical degree from the University of Heidelberg, Germany. He is a fully trained head, neck, ear, nose, and throat surgeon. He began work as an Assistant Doctor and was then appointed as an otolaryngology specialist, before being employed as a Consultant at the Department of Otolaryngology at the University of Heidelberg, Germany.
From 2000 to 2004, Prof. Dietz worked as an Assistant Professor at the Department of Otolaryngology; in 2004 he was appointed as Chairman and Professor of the ENT Department at the University of Leipzig.
He specializes in head and neck oncology, ear surgery, nose and sinus surgery (FESS), laryngeal framework surgery, salivary gland surgery and surgery of the facial nerve. He has been conducting clinical trials since 1993, and is involved in teaching and developing new Harvard-based teaching strategies at the universities of Heidelberg and Leipzig.
Prof. Dietz is a member of several academic and scientific societies. He serves as a board member of the Innovation Centre of Computer Assisted Surgery and the German National Head and Neck Oncology Group. He is a board member of the German Larynx Preservation Group (Deutschen Organerhaltstudiengruppe), and serves as a scientific council member for the European Laryngeal Society. Prof. Dietz is also a Member of Honor of the Royal Belgian ENT Society and the Indian Head and Neck Foundation. He is director of the IRDC-Academy Leipzig and is an editor of the scientific German journal Laryngo-Rhino-Otologie (Thieme Germany).
Recent publications include:• Dietz, A. and Wichmann, G. (2011) Translational research in head
and neck cancer. Biological characteristic and general aspects. HNO. 59: 874–84.
• Mozet, C., Wichmann, G., and Dietz, A. (2011) Translational approaches in cancer stem cell research. HNO. 59: 859–65.
• Boehm, A., Wichmann, G., Mozet, C., et al. (2010) Current therapy options in recurrent head and neck cancer. HNO. 58:762–9.
Prof. Dietz has reported consultancy and/or honoraria fees from Merck Serono.
Professor
ANDREAS DIETZ Chairman
Clinic of Otolaryngology
University of Leipzig
Leipzig, Germany
Prof. Martin Dreyling is Professor of Medicine and Head of the Lymphoma Program at the Department of Medicine III, University Hospital Großhadern, Germany.
Prof. Dreyling studied at the universities of Düsseldorf, Giessen, Tübingen and Würzburg in Germany. He completed his clinical training at the universities of Bonn, Münster, Göttingen and Munich in Germany. He worked as a Visiting Scientist at the University of Chicago, USA, from 1992 to 1995.
He now focuses on the molecular basis of malignant transformation, cell cycle dysregulation, and secondary genetic alterations, as well as biological prognostic factors in malignant lymphoma. He is also interested in innovative therapeutic approaches, including novel antibodies and molecular targeted approaches like proteasome and mTOR inhibitors and immune modulators.
Prof. Dreyling is a member of various societies and organizations including the American Society of Clinical Oncology, American Society of Hematology, the Germany Association for Hematology and Oncology, the European Hematology Association, and the European Society for Medical Oncology (ESMO). He is Coordinator of the European MCL Network and Assistant Coordinator of the German Low Grade Lymphoma Study Group. He has co-authored numerous scientific papers, book chapters, and abstracts in international peer-reviewed journals.
Recent publications include:• Zimmermann, H., Choquet, S., Dierickx, D., et al. (2013) Early
and Late Posttransplant Lymphoproliferative Disorder After Lung Transplantation-34 Cases From the European PTLD Network. Transplantation. 96: e18-e19.
• Ferrero, S. and Dreyling, M. (2013) The current therapeutic scenario for relapsed mantle cell lymphoma. Current Opinion in Oncology. 25: 452–62.
• Montoto, S., Corradini, P., Dreyling, M., et al. (2013) Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party. Haematologica. 98: 1014–21.
Professor Martin Dreyling has reported consultancy and/or honoraria fees from Celgene, Janssen, Pfizer, Roche, and Mundipharma.
Professor
MARTIN DREYLING MD
Professor of Medicine
University Hospital Großhadern
Munich, Germany
Professor Simone Ferrero is a Research Fellow in the Department of Molecular Biotechnologies and Health Sciences within the Division of Hematology at the University of Torino, Italy.
Prof. Ferrero completed a degree in Medicine and Surgery in 2007 and was awarded a PhD in Hematology in 2012 from the University of Torino, Italy. He also earned a German language degree in 2012 from Goethe Institut, Germany. He worked as a Post-Doctoral Fellow in the Division of Hematology for the University of Torino and he was a Research Fellow in the Department of Internal Medicine at the University Hospital Munich, Germany, until 2013.
His main interests are lymphoproflierative diseases, disease assessment in non-Hodgkin lymphoma and multiple lymphoma, and the molecular pathogenesis of lymphoma and myeloma. Further interests include the genetics of immunoglobulin genes, and biological prognostic factors in non-Hodgkin lymphoma and chronic lymphocytic leukaemia.
Prof. Ferrero is a member of the Editorial Board of Expert Opinion on Drug Metabolism and Toxicology.
Recent publications include:• Ferrero, S., Monitillo, L., Mantoan, B., et al. (2013) Rituximab-based
pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma. Annals of Hematology. [Epub ahead of print]
• Ferrero, S., Drandi, D., Mantoan, B., et al. (2011) Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms. Hematological Oncology 29: 167–76.
• Ladetto, M., Pagliano, G., Ferrero, S., et al. (2010) Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thealidomide, and dexamethasone in patients with autografted myeloma. Journal of Clinical Oncology 28: 2077–84.
Professor Simone Ferrero has reported no consultancy or honoraria fees.
Professor
SIMONE FERREROMD, PhD
Research Fellow
Division of Hematology
Department of Molecular Biotechnologies
and Health Sciences
University of Torino, Italy
Dr. Marina Garassino is a Medical Consultant at the Medical Oncology Division of the National Cancer Institute of Milan, Italy.
Dr. Garassino received her medical degree in 1995 and achieved her board specialisation in Oncology in 1999 from the University of Milan. She then continued her training in oncology at various European institutions. From 2005 to 2011, she held a clinical post at the Fatebenefratelli Ophthalmic Hospital in Milan; in 2001, she founded the AIOM Giovani (Italian Young Oncologists Committee). She specialises in thoracic oncology and is coordinator of the TAILOR trial (NCT00637910).
Dr. Garassino serves on several national and international committees and task forces. She is an active member of ESMO as a Spotlights Editor and member of the Publishing Working Group; she is also serving as the ESMO National Representative in Italy 2012-2014. She is also a member of the ESMO Lung Cancer Faculty and the ESMO Public Policy Committee, and served on the local committee for the ESMO Congress 2010 in Milan.
Recent publications include:• Garassino MC, Martelli O, Broggini M, et al. Erlotinib versus
docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol 2013; 14(10):981–8.
• Garassino MC, Piva S, La Verde N, et al. Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients. PLoS One. 2013;8(4):e59981. doi: 10.1371/journal.pone.0059981. Epub
2013 Apr 5.
Dr. Marina Garassino has reported consultancy and/or honoraria fees from Eli Lilly and Boehringer Ingelheim.
Doctor
MARINA GARASSINOMD
Medical Consultant
Medical Oncology Division
National Cancer Institute of Milan, Italy
Dr. John B. Haanen is Head of the Division of Medical Oncology and Staff Scientist in the Division of Immunology at the Netherlands Cancer Institute, Amsterdam, the Netherlands. He is also Professor of Translational Immunotherapy of Cancer at Leiden University Medical Centre, the Netherlands.
Dr. Haanen received his medical degree from the University of Leiden, then completed a PhD on human CD4+ helper T cells at the Department of Immunohematology and the Blood Bank of the Leiden University Medical Centre and the DNAX Research Institute in California, USA. He then trained in internal medicine at Leiden University Medical Centre and at Bronovo Hospital in The Hague, the Netherlands. He also trained in intensive care medicine at Leiden University Medical Centre, and in immunology and medical oncology at the Netherlands Cancer Institute.
His research focuses on the translation of novel immunotherapy and targeted therapy strategies into clinical practice. His clinical medical oncology practice is focused on melanoma and renal cell carcinoma patients. He holds the UICC/Dutch Cancer Society International Cancer Technology Transfer Fellowship.
Dr. Haanen is a Co-founder of the Amsterdam Biotherapeutics Unit and Chairman of The Dutch Tumor Immunology Working Party for renal cell carcinoma. He serves on various advisory boards and committees, including the editorial board of Current Oncology Reports. Recent publications include:• Kelderman, S., van der Kooij, M.K., van den Eertwegh, A.J., et
al. (2013) Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O). Acta Oncologica. [Epub ahead of print]
• Blank, C.U., Hooijkaas, A.L., Haanen, J.B., et al. (2011) Combination of targeted therapy and immunotherapy in melanoma. Cancer Immunology, Immunotherapy. 60: 1359–71.
• van der Hiel, B., Blank, C.U., Haanen, J.B., et al. (2013) Detection of early onset of hypophysitis by (18)F-FDG PET-CT in a patient with advanced stage melanoma treated with ipilimumab. Clinical Nuclear Medicine. 38: e182–4.
Dr. John B. Haanen has reported no consultancy or honoraria fees.
Doctor
JOHN HAANENMD, PhD
Head, Division of Medical Oncology
The Netherlands Cancer Institute
Amsterdam, the Netherlands
Dr. Robert A. Huddart is a Reader and Honorary Consultant at the Institute of Cancer Research (ICR) in the United Kingdom, and is an Honorary Consultant in Urological Oncology at the Royal Marsden Hospital (RMH) in London.
Dr. Huddart completed his medical degree at Oxford University, then studied surgery at the University of London. He trained in Clinical Oncology at RMH and became a Fellow of the Royal College of Radiologists. He undertook a PhD in the Genetics of Testicular Cancer at ICR. In 1996, he was appointed as Senior Lecturer and Honorary Consultant in Clinical Oncology at ICR and RMH, and became Team leader in 2002. Dr. Huddart has worked as a Reader in Urological Oncology since 2007.
He specializes in the management of urological cancer. His clinical interests cover all medical aspects of prostate, bladder, and testicular cancer, with a particular research interest in bladder and testicular cancer. He has led trials for ICR and RMH in both areas. His work particularly focuses on developing improvements in conservative treatment options in muscle-invasive bladder cancer.
Dr. Huddart is the former chair and currently a member of the NCRI testis cancer study group, the NCRI bladder cancer study group and its chemotherapy subgroup and the CTRAD group. He is also Chief Investigator of the TE22 and TE23 studies and Co-investigator of the TRISST, 111 and Gem TIP studies. He is part of the trial development team of the TIGER trial, Chair of the South East England Testicular Cancer Network and a peer reviewer for the National Cancer Peer Review Team. In bladder cancer he was Chief Investigator for the SPARE trial of selective bladder preservation and the IDEAL study. He was also Co-Chief Investigator on the BC2001 trial and Co-Investigator for the BOXIT and ToTem trials.
Recent publications include:• Ruark, E., Seal, S., McDonald, H., et al. (2013) Identification of nine
new susceptibility loci for testicular cancer, including variants near DAZL and PRDM14. Nature Genetics. 45: 686–9.
• Horwich, A., Dearnaely, D.P., Sohaib, A. et al. (2013) Neoadjuvant carboplatin before radiotherapy in stage IIA and IIB seminoma. Annals of Oncology. 24: 2104–7.
• Creak, A., Hall, E., Horwich, A., et al. (2013) Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up. British Journal of Cancer. 109: 651–7.
Dr. Robert A. Huddart has reported he is a co-author on the following two studies discussed: ‘Neo-adjuvant carboplatin before radiotherapy in Stage IIA and Stage IIB seminoma’ and ‘Identification of nine new susceptibility loci for testicular cancer, including variants near DAZL and PRDM14’. Dr. Huddart has no additional potential conflicts of interest to declare.
Doctor
ROBERT A. HUDDARTMD, PhD
Reader & Honorary Consultant in Urological Oncology
Institute of Cancer Research & Royal Marsden Hospital
Sutton Surrey, United Kingdom
Dr. Maren Knödler is Chief Physician and head of the ambulance on site at UCCL, University of Leipzig, Leipzig, Germany.
After receiving her medical degree in 2006, Dr. Knödler completed her residency training in internal medicine from 2006 to 2012 at Charité’s Division of Haematology and Oncology in Berlin. During this time, she was also an investigator for the coordinating centre for clinical trials at Charité (2006-2007).
Dr. Knödler is currently an investigator for numerous national and international Phase II and III trials evaluating treatments for haematology and oncology disorders and is the study coordinator and head of several national studies on specific antitumour therapy.
Dr. Knödler is a member of various working groups and societies, including the working group for Head and Neck Cancer and the working group for Young Medical Oncologists in the Association of Medical Oncology (AIO), which is connected to the German Cancer Society (Deutschen Krebsgesellschaft), as well as the German Society of Haematology and Oncology (DGHO).
Recent publications include:• Tinhofer I, Klinghammer K, Weichert W, et al. (2011) Expression
of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Clin Cancer Res. 17:5197-204.
• Klinghammer K, Knödler M, Schmittel A, et al. (2010) Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Clin Cancer Res. 16:304-310.
Dr. Maren Knödler is participating in research projects sponsored by Merck Serono and Sanofi.
Doctor
MAREN KNÖDLERMD
University Cancer Center (UCCL)
University of Leipzig,
Leipzig, Germany
Professor Vesa V. Kataja is Professor of Clinical Oncology at the Department of Health Sciences, University of Eastern Finland, Finland, and Head Physician of the Cancer Center, Kuopio University Hospital (KUH), also in Finland.
Prof. Kataja studied in Wales, Canada, and Finland and received his physician’s license in 1985. He acquired the state qualification as Specialist in Medical Oncology and Radiotherapy in 1993. Following this, he was employed by the Sandoz Clinical Development Centre Ltd. in Frimley, United Kingdom, as a Medical Adviser in Oncology. From 1995 to 2006, he acted as the Deputy Head Physician at the Department of Oncology, KUH and as Consulting Clinical Oncologist in two hospitals. He then worked as Head of the Department of Oncology and Medical Director of the Conservative Clinics at Vaasa Central Hospital, Finland, until 2010.
Prof. Kataja’s basic research interest has been in the field of breast cancer genetics; however, his clinical research focuses on genitourinary tumors. He is a member of many professional societies, scientific boards and working groups internationally, including the Publishing Working Group and the Guidelines Working Group of the European Society for Medical Oncology (ESMO). He is an active member of ESMO also as a Spotlights Editor and has previously served as a National Representative. He is an ad hoc reviewer for several oncology journals.
Recent publications include:• Joensuu, H., Kellokumpu-Lehtinen, P.L., Houvinen, R., et al. (2013)
Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica. [Epub ahead of print]
• Justenhoven, C., Obazee, O., Winter, S., et al. (2013) The UGT1A6_19_GG genotype is a breast cancer risk factor. Frontiers in Genetics. 4: 104.
• Loi, S., Michiels, S., Lambrechts, D., et al. (2013) Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer. Journal of the National Cancer Institute. 105: 960–7.
Professor Vesa V. Kataja has reported consultancy and/or honoraria fees from Astellas, Bayer, Janssen Cilag, MSD, Pfizer, and Sanofi.
Professor
VESA V. KATAJA MD, PhD
Professor of Clinical Oncology
University of Eastern Finland
Finland
Dr. Kristiina Koskela is an Oncologist within the radiotherapy unit of the Cancer Center at Kuopio University Hospital in Kuopio, Finland.
Dr. Koskela received her state qualification in medicine and her physician’s licence in 2005 from Oulu University, Finland. Since 2009 she has worked in the field of oncology; she acquired the state qualification as Specialist in Clinical Oncology in 2013. She teaches oncology at Savonia University of Applied Sciences, and also works as a consultant at North Karelia Central Hospital, both in Finland.
Dr. Koskela’s research interest lies in radiation oncology, specifically HDR and LDR brachytherapy. She is the principal investigator in the phase III clinical trial BRAVEROBO.
Dr. Kristiina Koskela has reported no consultancy or honoraria fees.
Doctor
KRISTIINA KOSKELAMD
Kuopio University Hospital
Kuopio, Finland
Dr. Amalia Milano is a Medical Doctor in the Division of Medical Oncology at San Bartolomeo Hospital in Sarzana, Italy.
Dr. Milano received her medical degree in 2000 and her specialisation in Oncology in 2004, both from the University of Naples Federico II in Naples, Italy. She then worked at the Hospital of Prato in Prato, and completed fellowships at Fondazione G. Pascale and the University of Naples Federico II, Italy and the Jules Bordet Institute, Belgium.
Recent key publications include:• Milano, A., Perri, F., Ciarmiello, A., et al. (2011) Targeted-therapy
and imaging response: a new paradigm for clinical evaluation? Reviews on Recent Clinical Trials. 6: 259–65.
• Apice, G., Milano, A., Bruni, G.S., et al. (2006) Medical treatment of gastrointestinal stromal tumors: state of the art and future perspectives. Reviews on Recent Clinical Trials. 1: 35–42.
Dr. Amalia Milano has reported no consultancy or honoraria fees.
Doctor
AMALIA MILANOMD
San Bartolomeo Hospital
Sarzana, Italy
Dr. Timothy J. Perren is a Consultant Medical Oncologist at the St James’s Institute of Oncology in the United Kingdom.
Dr. Perren trained in Medical Oncology first in Birmingham and subsequently at the Royal Marsden Hospital in London. He was a Senior Lecturer in Medical Oncology at the University of Leeds and St James’s University Hospital prior to becoming an NHS Consultant Medical Oncologist in April 2000. His clinical interests span breast and gynaecological cancers, and he has a long-standing interest in clinical trials that explore the development of new and better treatments for these cancers.
Dr. Perren has been a member of the UK National Cancer Research Institute’s Gynaecological Cancer clinical Studies Group since its inception; he also serves on the clinical trial steering committees for a number of the current and recent national phase III trials in breast and gynaecological cancers.
Recent publications include:• Kehoe, S., Hook, S., Nankivell, M., et al. (2013) Chemotherapy or
upfront surgery for newly diagnosed advanced ovarian cancer: Results from the MRC CHORUS trial. Journal of Clinical Oncology. 31: No 15_suppl 5500.
• Collinson, F.J., Seligmann, J., and Perren, T.J. (2012) Ovarian cancer: advances in first-line treatment strategies with a particular focus on anti-angiogenic agents. Current Oncology Reports. 14: 509–18.
• Collinson, F.J., Hall, G.D., Perren, T.J., et al. (2008) Development of antiangiogenic agents for ovarian cancer. Expert Review of Anitcancer Therapy. 8: 21–32.
Dr. Timothy J. Perren has reported consultancy and/or honoraria fees from Roche and Novartis.
Doctor
TIMOTHY J. PERREN MD, FRCP
Consultant Medical Oncologist
St James’s Institute of Oncology
Leeds, United Kingdom
Born in Cagliari on 13 November 1979, she graduated in Medicine and Surgery at Cagliari University (110/110 cum laude), and her post-graduate education continued with a Medical Oncology Specialization at Milan University (70/70 cum laude).
Since 2004 she has been working at the Istituto Nazionale per lo Studio e la Cura dei Tumori in Milan, and is currently dedicated to the research and treatment of Neuroendocrine Tumours. She is a Member of the ENETS GEP-NET Center of Excellence at Istituto Nazionale Tumori Milano in Milan, and she participates actively as an Expert in Medical Oncology Tumour-board of GEP-NET Center.
She is a member of leading national and international associations in Medical Oncology, including the Associazione Italiana de Oncologia Medica (AIOM) and the European Society for Medical Oncology (ESMO). She has actively participated as a co-investigator in numerous clinical trials in “Good Clinical Practice” carried out at the Istituto Nazionale Tumori Milano, and she is involved as a clinician as well as a co-investigator in research on Neuroendocrine and Gastrointestinal tumours.
She has written and participated in the preparation of scientific publications on cancer issues. Recent publications include:• Buzzoni R, Pusceddu S, Damato A, et al. Malignant
pheochromocytoma and paraganglioma: future considerations for therapy. Q J Nucl Med Mol Imaging. 2013 Jun;57(2):153–60
• Pusceddu S, Buzzoni R, De Braud F. Pancreatic well-differentiated neuroendocrine neoplasms (pWDNENs): what place for everolimus and sunitinib derived from ESMO clinical practice guidelines in the therapeutic algorithm? Ann Oncol. 2013 May;24(5):1415–6
Dr. Pusceddu has declared no potential conflicts of interest.
Doctor
SARA PUSCEDDUMD
Oncologist, Medical Oncology Division
National Cancer Institute
Milan, Italy
Dr. Mattea Reinisch is a Resident in the Department of Obstetrics and Gynecology at Bürgerhospital in Frankfurt, Germany, and works with the German Breast Group.
Dr. Reinisch graduated from Medical School in 2007, at the Charité, Medical University Berlin, Germany. She completed clinical rotation in teaching hospitals in Vietnam and Australia and participated in the Flims Workshop in 2012. From 2007 to 2008, she worked as a Resident at Helios Clinics Berlin, Germany, where she focused on clinical breast cancer and clinical studies. She was then appointed a Resident at the German Breast Group and changed her focus to elderly and male breast cancer patients.
Recent publications include: • Denkert C, Huober J, Loibl S, et al. HER2 and ESR1 mRNA
expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer. Breast Cancer Res. 2013 Feb 7;15(1):R11. [Epub ahead of print]
Dr. Mattea Reinisch has reported no consultancy or honoraria fees.
Doctor
MATTEA REINISCHMD
Resident, Department of Obstetrics and Gynecology
Bürgerhospital
Frankfurt, Germany
Dr. Marianna Rondini is a Medical Doctor in the Division of Medical Oncology at Sant’ Andrea Hospital in La Spezia, Italy. Dr. Rondini obtained her medical degree in 2000 from the University of Pisa, Italy, and focused her dissertation on breast cancer. In 2004, she gained a specialisation in Oncology by completing a phase II study in breast cancer, again at the University of Pisa. She then worked at Azienda USL 2 in Lucca, and completed fellowships at Sant’ Andrea Hospital, Ospedale Unico Versilia, Azienda USL 2 and the Medical School at the University of Pisa in Pisa, Italy.
Recent publications include:• Camerini, A., Valsuani, C., Mazzoni, F., et al. (2010) Phase II trial of
single-agent oral vinorelbine in elderly (> or =70 years) patients with advances non-small-cell lung cancer and poor performance status. Annals of Oncology. 21: 1290–5.
• Camerini, A., Rondini, M., Garrone, O., et al. (2009) Fulvestrant treatment is associated with cholesterol plasma level reduction in hormone-receptor-positive metastatic breast cancer patients. Cancer Biology and Therapy. 8: 1450–5.
• Valsuani, C., Siclari, O., Camerini, A., et al. (2009) Sorafenib in a patient with advanced hepatocellular carcinoma and serious impairment of left ventricular function: a case report. Cases Journal. 2: 9133.
Dr. Marianna Rondini has reported that she has not received consultancy or honoraria fees.
Doctor
MARIANNA RONDINIMD
Division of Medical Oncology
Sant’ Andrea Hospital
La Spezia, Italy
Dr. Patrick Roth is an Attending Physician at the Department of Neurology of the University Hospital Zurich, Switzerland.
Dr. Roth specialises in the interdisciplinary management of brain tumour patients. He is involved in various clinical trials and is involved in preclinical research to develop novel therapeutic strategies, with a focus on immunotherapeutic approaches for brain tumour patients. His current research focuses are the mechanisms underlying glioma immune escape, novel approaches to enhance the immunogenicity of glioma cells, and the analysis of new compounds for anti-glioma therapy.
Recent publications include:• Roth, P., Wick, W., and Weller, M. (2013) Anaplastic
Oligodendroglioma: A New Treatment Paradigm and Current Controversies. Current Treatment Options in Oncology. [Epub ahead of print]
• Vogetseder, A., Thies, S., Ingold, B., et al. (2013) av-Intergrin isoform expression in primary human tumors and brain metastases. International Journal of Cancer. [Epub ahead of print]
• Roth, P., Silginer, M., Goodman, S.L., et al. (2013) Integrin control of transforming growth factor- pathway in glioblastoma. Brain. 136: 564–76.
Dr. Patrick Roth has reported consultancy and/or honoraria fees from MSD and Roche.
Doctor
PATRICK ROTHMD
Department of Neurology
University Hospital Zurich
Zurich, Switzerland
Dr. Mausam Singhera is a Clinical Research Fellow at the Institute of Cancer Research and The Royal Marsden NHS Foundation Trust in Surrey, UK. She is working towards a Doctor of Medicine (Res) degree; her project evaluates survivorship issues in testicular cancer survivors. She completed her medical training at Jawaharlal Nehru Medical College in Aligarh, India, and then trained in Clinical Oncology in 2010 in the UK.
Recent publications include:• Maclean, J., Fersht, N., Singhera, M., et al. (2013) Multi-disciplinary
management for patients with oligometastases to the brain: results of a 5 year cohort study. Radiation Oncology. 8: 156.
• Singhera, M. and Huddart, R. (2013) Testicular cancer: Changing patterns of incidence in testicular germ cell tumours. Nature Reviews Urology. 10: 312–4.
• Selvadurai, E.D., Singhera, M., Thomas, K., et al. (2013) Medium-term Outcomes of Active Surveillance for Localised Prostate Cancer. European Urology. S0302–2838.
Dr. Mausam Singhera has reported no consultancy or honoraria fees.
Doctor
MAUSAM SINGHERAMD
Clinical Research Fellow
Institute of Cancer Research and The Royal
Marsden NHS Foundation Trust
Surrey, UK
Dr. Ghazaleh Tabatabai is an Attending Physician at the Department of Neurology of the University Hospital Zurich, Switzerland. She is involved in the interdisciplinary management of brain tumour patients.
Dr. Tabatabia specialises in clinical and preclinical neuro-oncology and aims to improve the therapeutic options for brain tumour patients. Her current research goals are to design cell-based gene therapies against malignant gliomas and to identify the “barcode” of glioma-initiating cells. She is also interested in the molecular mechanisms of therapy resistance.
Dr. Tabatabai is the study coordinator of several phase II clinical trials.
Recent publications include:• Wehrl, H.F., Schwab, J., Hasenbach, K., et al. (2013) Multimodal
elucidation of choline metabolism in murine glioma model using magnetic resonance stpectroscopy and 11C-choline positron emission tomography. Cancer Research. 73: 1470–80.
• Hasenbach, K., Wiehr, S., Herrmann, C., et al. (2012) Monitoring the glioma tropism of bone marrow-derived progenitor cells by 2-photon laser scanning microscopy and positron emission tomography. Neuro-oncology. 14: 471–81.
• Maurer, G.D., Tritschler, I., Adams, B., et al. (2009) Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. Neuro-Oncology. 11: 747–56.
Dr. Ghazaleh Tabatabai has reported consultancy and/or honoraria fees from MSD and Roche.
Doctor
GHAZALEH TABATABAIMD, PhD
Department of Neurology
University Hospital Zurich
Zurich, Switzerland
Dr. Hans van Thienen works as a Medical Oncologist at the Netherlands Cancer Institute at Antoni van Leeuwenhoek Hospital in Amsterdam.
Dr. van Thienen received his medical degree from the University of Amsterdam and then received a PhD for his work on atherosclerosis. During his residency in internal medicine, he specialised in medical oncology.
He now focuses on the treatment of patients with renal cancer and melanoma, and the application of novel immunotherapy and targeted therapy strategies in clinical practice.
Dr. Hans van Thienen has reported no consultancy or honoraria fees.
Doctor
HANS VAN THIENENMD, PhD
Division of Medical Oncology
The Netherlands Cancer Institute
Amsterdam, The Netherlands
Dr. Konstantinos Tryfonidis is a clinical research fellow at EORTC HQ, appointed on behalf of the Breast Cancer Group and Elderly Task Force. Dr. Tryfonidis studied for his basic medical education in 2001 at the University of Brno, Czech Republic. From 2002 to 2003, he served as a doctor in Corinth, Greece, and then from 2003 to 2005, he was appointed the Responsible Clinician for clinical trials in the field of cardiology at the Department of Cardiology in the General Hospital of Corinth. In 2006, Dr. Tryfonidis began his residency in internal medicine in the General Hospital of NIMITS in Athens. He completed his residency in medical oncology at the University Hospital of Herakilon, Greece from 2009-2012. He is currently completing his PhD thesis on pharmacogenomics in non-small cell lung cancer in the Laboratory of Cancer Biology, University of Crete, Greece. Dr. Tryfonidis has been involved in phase II and III clinical trials in breast cancer and geriatric oncology. However, his primary interest at EORTC is the development of a clinical research project on resistant mechanisms in breast cancer. Recent publications include:• Karachaliou, N., Ziras, N., Syrigos, K., et al. (2012) A multicenter
phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline – and taxane – pretreated patients with metastatic breast cancer. Cancer Chemotherapy and Pharmacology. 70: 169–76.
• Papadaki, C., Sfakianaki, M., Loannidis, G., et al. (2012) ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer. Journal of Thoracic Oncology. 7:663–71.
• Karachaliou, N., Kouroussis, Ch., Papakotoulas, P., et al. (2012) A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline – and taxane – pretreated patients with metastatic breast cancer. Cancer Chemotherapy and Pharmacology. 69:1345–52.
Dr. Konstantions Tryfonidis has reported no consultancy or honoraria fees.
Doctor
KONSTANTINOS TRYFONIDISMD
Medical Oncologist
EORTC HQ
Brussels, Belgium
Dr. Francesc Pons Valladares is Staff Physician in the Medical Oncology Department at the University Hospital del Mar, Spain. He works in the Gastrointestinal and Genitourinary Tumor Section, where he is a member of the Genitourinary multidisciplinary board team and the Genitourinary Research Team.
Dr. Pons Valladares received his medical degree from the University of Barcelona, Spain. He then specialised in Medical Oncology at the Medical Oncology Department of the Institut Català d’Oncologia, Spain. In addition, he spent some time in the Translational Research Laboratory IDIBELL at the same institution. He has completed postgraduate studies in Clinical Sciences Investigation.
He specialises in genitourinary tumours and has been a co-investigator in several phase II and III trials, as well as some genitourinary translational research projects. He is also a collaborator for the Medicine Faculty of the Universitat Autònoma de Barcelona, Spain. Dr. Valladares has been a reviewer for the journals European Urology and Annals of Oncology.
Recent publications include:• Fuertes S, Setoain X, Lopez-Guillermo A, et al. Interim FDG PET/
CT as a prognostic factor in diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2013 Apr;40(4):496–504. doi: 10.1007/s00259–012-2320–8. Epub 2013 Jan 23.
Dr. Francesc Pons Valladares has reported no consultancy or honoraria fees.
Doctor
FRANCESC PONS VALLADARES MD
Staff Physician
Medical Oncology Department
University Hospital del Mar
Barcelona, Spain
Professor Gunter von Minckwitz is the Managing Director of the breast cancer research facility German Breast Group Research Institute. He is the Alternate Director at Senologic Oncology in Düsseldorf, Germany, and a Professor at the University of Frankfurt.
Prof. von Minckwitz studied medicine from 1983 to 1990 at the University of Heidelberg, Germany, and received his doctorate there in 1991. He worked as a Medical Assistant first at the local Women’s Hospital. From 1998 to 2008, he served as Chief Physician and from 2003 to 2009, he worked as an Assistant Medical Oncologist.His research interests include systemic treatment of all stages of breast cancer and he has led a large number of national and international clinical trials. He has improved the infrastructure for breast cancer trials all over Germany; he founded (and previously led) the development of the National Treatment Guidelines for Breast Cancer, published by the German research group AGO.
Prof. von Minckwitz is a member of the board of the directors of the Breast International Group, a member of the St. Gallen consensus panel and serves on the Steering Committee of the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). He is on the editorial board for Breast Care, and acts as a scientific advisor for Senology and Gyn Spectrum.
Recent publications include:• von Minckwitz, G., Mobus, V., Schneeweiss, A., et al. (2013)
German Adjuvant Intergroup Node-Positive Study: A Phase III Trial to Compare Oral Ibandronate Versus Observation in Patients With High-Risk Early Breast Cancer. Journal of Clinical Oncology. [Epub ahead of print]
• Denkert, C., Loibl, S., Muller, B.M., et al. (2013) Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant Gepar Trio trial. Annals of Oncology. [Epub ahead of print]
• Marinovich, M.L., Macaskill, P., Irwig, L., et al. (2013) Meta-analysis of agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapy. British Journal of Cancer. [Epub ahead of print]
Prof. Gunter Von Minckwitz has reported consultancy and/or honoraria fees from Roche and Glaxo SK.
Professor
GUNTER VON MINCKWITZ MD
Managing Director
German Breast Group
Neu-Isenburg, Germany
Dr. Alison C. Young is a Consultant Medical Oncologist within the Women’s Gynaecological team at St. James’s Institute of Oncology in Leeds and at the Leeds Cancer Centre, UK.
Dr. Young trained in Medical Oncology in Leeds; she has been working as an NHS Medical Oncology Consultant since January 2012. Her clinical interests are in gynaecological cancers and acute oncology. She is the lead for Acute Oncology in Leeds and is developing new the acute oncology service for the Leeds Teaching Hospitals.
Recent publications include:• Young, A.C., Craven, R.A., Cohen, D., et al. (2009) Analysis of VHL
Gene Alterations and their Relationships to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma. Clinical Cancer Research. 15: 7582-7592.
• McCormick, R.I., Blick, C., Ragoussis, J., et al. (2012) miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis. British Journal of Cancer. 108: 1133–42.
• Young, A., Madi, A., Treanor, D., et al. (2010) Fulminant hepatic failure in a patient with advanced extragonadal germ cell tumour. BMJ Case Reports. pii: bcr0120102661.
Dr. Alison C. Young has reported consultancy and/or honoraria fees from Roche.
Doctor
ALISON YOUNGMD, MRCP
Consultant Medical Oncologist
St James’s University Hospital
Leeds, United Kingdom
Dr. Zbigniew (Ben) Zylicz is Head of the Research and Education Department of Hildegard Hospiz in Basel, Switzerland. He also helped to set up the Chair of Palliative Medicine at the University of Basel, Switzerland.
Dr. Zylicz completed his medicine degree in 1979, in Poland. From 1980 he trained in Internal Medicine and Medical Oncology at the universities of Nijmegen and Groningen in the Netherlands. In 1988 he successfully defended his thesis and was granted the title of Doctor at the University of Nijmegen.
Having worked as a clinician in a regional hospital, Dr. Zylicz accepted the position of Medical Director at the Hospice Rozenheuvel in Rozendaal – one of the first Dutch hospices. Here he helped to develop palliative care in the Netherlands, for which he was decorated by HM Queen Beatrix with the Officers’ Cross of Orange Nassau. From 2005 to 2010, he formally specialized in Palliative Medicine as the medical director of a large hospice in Hull in the United Kingdom.
Dr. Zylicz specializes in pain, itch, and pruritus in cancer, as well as opioid pharmacology, opioid induced hyperalgesia, and end-of-life medical ethics. He has edited several academic textbooks and authored hundreds of articles in peer-reviewed journals.
Recent publications include:• Hanna, M. and Zylicz, Z. (2013) Cancer Pain. London: Springer.• Zylicz, Z. (2004) Pruritus in advanced disease. Oxford: Oxford
University Press.
Dr. Zylicz has reported consultancy and/or honoraria fees from Grünenthal and Mundipharma.
Doctor
ZBIGNIEW (BEN) ZYLICZMD, PhD
Consultant in Palliative Medicine
Hildegard Hospiz
Basel, Switzerland
